Loading...

ORMP ORAMED PHARMACEUTICALS INC Dividend Policy Changes 8-K Filing

RMD

RMP

ORAMED PHARMACEUTICALS INC

(ORMP)

2026 8-K

Acquisition Completed

Warrant Agreement

Share Purchase Agreement

Financial Update

Director Resignation

Warrant Repurchase

Financial Results Report

Dividend Announcement

Share Repurchase Agreement

Warrants Repurchase

Stockholder Meeting Summary

Asset Acquisitions

Royalty Agreement

License Agreement

Joint Venture Agreement

Payment Deferral Agreement

Securities Agreement

Securities Agreement

Clinical Trial Agreement

Securities Agreement

Annual Meeting of Stockholders

Stock Buyback Program

Merger of Equals

Appointment of CFO

Resignation of CFO

Payment Received

Investment Deal

Appointment of Director

Agreement for Stock Offering

Joint Venture Agreement

Resignation of Director

Investment Deal

Appointment of Director

Acquisition Agreement Termi...

Stock Purchase Agreement

Amendment to Stock Purchase...

Stock Purchase Agreement

Share Purchase Term Sheet

Appointment of Director

Amendments to Bylaws

Phase 3 Clinical Trial Results

External Links:

On January 7, 2026, Oramed Pharmaceuticals Inc. announced they received an $18 million payment from Scilex Holdings Inc. and declared a cash dividend of $0.25 per share, amounting to about $10.5 million, payable on January 26, 2026, to shareholders of record as of January 16, 2026.

AI Assistant

ORAMED PHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.